WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical (BMRN) reported new data from
an investigator-led analysis of the Phase 2 111-205 study, which showed that
children with achondroplasia treated with VOXZOGO experienced increases in bone
length while maintaining bone strength. The analysis, after approximately five
years of therapy, suggested that treatment allowed the bone to remain strong as
it lengthened.

VOXZOGO is approved in the U.S. and Japan to increase linear growth in children
of all ages with achondroplasia with open epiphyses. In the U.S., the indication
is approved under accelerated approval based on an improvement in annualized
growth velocity.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX